Purpose of Review Cardiovascular disease (CVD) is the leading cause of death in the USA and globally. There is significant evidence implicating genetic and dietary factors in the development and progression of CVD and its risk factors. Nutritional genomics is a comparatively new field of science that focuses on the relationship of individual genetic variation with response to nutrition. The purpose of this review is to summarize recent progress, in the field of nutritional genomics as it relates to cardiovascular disease. Recent Findings Evidence from recent studies has shown significant effects of gene-diet interactions on CVD biomarkers and the development and progression of CVD. The cardiovascular effects of gene-nutrient interactions with respect to macronutrients and genes such as FTO, ACE, PPARs, TCF7L2, BDNF, MC4R, APOAs, and FADS have shown consistent results across age groups and populations, whereas gene-nutrient interaction effects of other genes have only been limited to specific ages, genders, or populations, and need to be validated and confirmed. Summary The identification of individual genetic variation influencing diet-related CVD risk is important and may inform future nutritional intervention studies. Although there is ample scientific evidence indicating that the genetic susceptibility to CVD can be modified by diet, we are still not at a stage where this information is easily translated into dietary plans. Thus, there is a need for better approaches to achieve precision in dietary data collection and streamline computational approaches for meaningful and effective nutritional interventions.
Introduction
Cardiovascular disease (CVD) refers to a group of disorders including coronary heart disease, cerebrovascular disease, peripheral arterial disease, rheumatic heart diseases, congenital heart disease, deep vein thrombosis, and pulmonary embolism [1, 2] . CVD is the number one cause of death globally, accounting for about one-third of deaths [3] . Although over three quarters of deaths take place in low-and middle-income countries, the USA is not far behind. In the USA, one in four deaths is attributed to CVD [3, 4] . Cardiovascular diseases are highly influenced by genetic factors [5, 6] , and there is also significant evidence implicating diet and lifestyle factors (e.g., obesity, sedentary behavior) in the development and progression of CVD and its risk factors [7, 8] . It is also known that diet and lifestyle at younger ages can influence the risk for disease risk at a later age. Differences in susceptibility to CVD based on genotypes, ethnicities, and environments have long intrigued people; more recently, there has been a growing interest in the role of individual genetic variation in response to nutrition in human populations [9, 10] and an increasing recognition that the interaction between genes and environment (e.g., diet/nutrition) can have a major impact on metabolic alterations. Thus, understanding the biological mechanisms underlying CVD and applying this knowledge are key components for management of CVD.
The discipline of nutritional genomics, focusing on the effects of nutrients or dietary constituents on the expression of genes (nutrigenomics) and the effects of genetic variation on the metabolic response of nutrients (nutrigenetics) [11•, 12-14, 15•] , is being increasingly recognized as a major This article is part of the Topical Collection on Cardiovascular Genetics player in disease risk. Obesity, type 2 diabetes/insulin resistance/glucose intolerance, hypertension, and dyslipidemia represent four modifiable CVD risk factors where there has been considerable progress related to nutritional genomics. Other CVD risk factors where nutritional genomics can be important to understand the etiological underpinnings include elevated oxidative stress and inflammation. Since genes, diet, and their interactions can have significant effect on disease risk, translating this science to practice is crucial for disease prevention and management. Most modifiable among the CVD risk factors are diet/nutrients [16, 17] , highlighting the importance of understanding the interaction between genes and diet in modulating CVD risk. However, key questions remain, e.g., is there enough scientific evidence to implicate genes, nutrients, and their interactions as significant contributing factors in CVD risk? And where are we in the field with respect to disseminating this information to patients or public, e.g., precision health (precision medicine and precision nutrition) [12] ? The purpose of this review is to summarize recent progress in the field of nutritional genomics related to cardiovascular disease research.
Obesity
Obesity, particularly abdominal obesity, is a key risk factor for CVD. According to a recently released report by the CDC, the prevalence of obesity, in 2015-2016, was 39.8% among adults and 18.5% among youth (cdc.gov accessed on Feb 1, 2018). It is well known that obesity is influenced by genetic and environmental factors. To date, more than 300 common single nucleotide polymorphisms (SNPs) affecting obesity and related phenotypes have been identified from genome-wide association and candidate gene studies [18] . The key genes that have been implicated in obesity and related phenotypes are fat mass and obesity-associated gene (FTO), melanocortin 4 receptor (MC4R), peroxisome proliferator-activated receptor gamma (PPARγ), transmembrane protein 18 (TMEM18), brain-derived neurotrophic factor (BDNF), pro-opiomelanocortin (POMC), neuronal growth regulator1(NEGR1), proprotein convertase subtilisin/ kexin type 1 (PCSK1), SH2B adaptor protein1 (SH2B1), leptin receptor (LEPR), and neurotrophic receptor tyrosine kinase 2 (NTRK2) with FTO showing the strongest and consistent signal across age groups, genders, and ethnicities [18-23, 24•, 25-29] . In a recent study of more than 339,000 individuals [23] , 97 loci were identified as associated with BMI, 56 of which were novel. However, all these 97 loci jointly explain only about 2.7% of the variation in BMI. This indicates that many more SNPs and other factors such as gene × gene and gene × environment interactions may explain the missing variance.
Epidemiological studies have shown that environment can exacerbate the effects of genes on obesity. Evidence has consistently pointed to the role of gene × diet interaction in the risk of obesity [19] . Most of the studies have focused on the interaction between genes and consumption of macronutrients as they relate to the development and/or progression of obesity. The best-characterized gene variants known to interact with dietary nutrients and affect obesity have been mostly identified using candidate gene approaches. These candidate variants are usually the top ranked in genome-wide association studies using some data reduction strategies. Of these genetic loci, FTO, BDNF, apolipoprotein A2 and A5 (APOA2 and APOA5), PPARγ, NEGR1, TMEM18, and LEPR have been extensively studied with respect to their interaction with diet [26] [27] [28] [29] [30] . In about 26,000 individuals from a cohort in Southern Sweden, NEGR1 SNP rs2815752 was associated with dietary intake (low fat and high carbohydrate intake) and the interaction of rs4923461 of BDNF with protein intake was significantly associated with BMI [26] . Protein intake was also found to affect the association between FTO and BMI in children and adolescents where the association between FTO variant and BMI was much weaker in lowprotein-intake groups compared to high-protein-intake groups [27] . Similarly, the association between FTO and BMI was found to be stronger in individuals with high fat intake than those with low fat intake [28, 29] which was replicated in three cohorts comprising of more than 9000 women from Nurses' Health Study, 6000 men from the Health Professionals Follow-Up Study, and 21,000 women from Women's Genome Health Study [30, 31] . Additionally, studies in children have shown the modification of the association between SNPs in APOA2, APOA5, and LEPR and obesity by dietary fat [32] . Most of the studies shown above have been conducted in individuals of European ancestry. However, the effects of FTO and its interaction with either protein or fat intake on BMI seem to expand across ethnicities to Asian Indians [33] .
Since single variants may not explain the complete phenotypic variation, taking into account multiple variants by computing a comprehensive genetic risk score (GRS) may be better to detect a significant portion of genetic variance affecting a phenotype. Following this approach, Qi et al. [30] found that an association between BMI and a multi-SNP GRS was stronger in individuals who consumed more fried foods than those with who did not. This specific GRS included 32 SNPs near genes related to the central nervous system such as FTO, BDNF, neurexin 3 (NRXN3), and TMEM18. The SNPs included in the GRS were selected based on previous genetic association results of BMI and/or obesity traits. The same group also showed the pronounced effects of sugar-sweetened beverage consumption on the association between a 32 SNP GRS and BMI [31] . In contrast, the CHARGE consortium (Cohorts for Heart and Aging Research in Genomic Epidemiology) reported the same 32 SNP GRS to be strongly associated with BMI in subjects eating a healthier diet that included self-reported intake of whole grains, fish, fruits, vegetables, nuts, etc. [20] .
In addition to macronutrient intake, dietary fiber intake was also found to modify the association between FTO and BMI. Using individual FTO SNPs and GRS created with FTO SNPs, the authors found that the association of FTO variants with BMI was stronger in individuals who consumed high levels of dietary fiber. Individuals with AA of rs11076023 [33] and TT and AT of rs3751812 [34] had lower abdominal obesity or waist circumference in those who had the highest fiber intake [33, 34] . A member of the superfamily of nonhaem-Fe(II) and 2-oxoglutarate (2OG)-dependent dioxygenases, FTO is believed to be involved in regulation of energy intake with a key role in nervous and cardiovascular system [35, 36] .
Type 2 Diabetes, Insulin Resistance, and Glucose Intolerance
Type 2 diabetes (T2D) is defined as hyperglycemia resulting from insufficient insulin secretion and/or utilization [37] . T2D is an independent risk factor for CVD. Similar to other CVD risk factors, T2D is under significant nutritional and genetic influence. Over 70 genes and 100 SNPs have been identified so far that are associated with T2D [38•] . Gene-nutrient interaction studies have identified interactions between western dietary patterns and variants in PPARγ, transcription factor 7-like 2 (TCF7L2) and FTO in influencing T2D. Mainly, rs1801282 (Pro12Ala) of PPARγ has been positively associated with insulin sensitivity [39, 40•] . Individuals with the ProPro were more responsive to increased polyunsaturated fatty acids (PUFA) intake than those with the ProAla or AlaAla genotypes [39] . The same group also showed the association between G protein-coupled receptor 120 (GPR120) loss-of-function variant (R270H) and the risk of T2D was higher with higher fat intake, particularly in H-carriers [40•] . Similarly, rs12573128 of TCF7L2 interacts with fat intake to affect insulin sensitivity as measured by HOMA-IR index and rs9939609 of FTO interacts with carbohydrate intake to affect T2D risk [41] . The role of BDNF in diabetes and Alzheimer's disease is known [42] . In a Korean study, the interaction between BDNF variants and energy and protein intake had significant effects on T2D and glucose intolerance. Individuals with rs6265 Val/Met and Met/Met variants had lower risk for T2D on high carbohydrate and low energy intake [42] .
Hypertension
Hypertension, characterized by high systolic blood pressure and/or high diastolic blood pressure, is associated with heart failure, renal disease, stroke, and cardiovascular death, and is highly modified by lifestyle changes [43] . It has been reported that, for individuals between the ages of 40-69 years, every 20 mmHg increase in systolic blood pressure and 10 mmHg increased in diastolic blood pressure doubles the risk for CVD [44, 45] . Weight loss, increased physical activity, and a healthy diet with decreased salt intake are some of the lifestyle modifications advocated for management of hypertension. Blood pressure is also influenced by genetic factors with its heritable component being 30-50% [46] . The reninangiotensin system (RAS) and its components play a major role in the regulation of hypertension [47] . The angiotensinconverting enzyme (ACE) is the key enzyme in controlling blood pressure, and polymorphisms in ACE, the gene encoding this enzyme, have been implicated in the risk for hypertension and CVD. In the Nutrigenomic Analysis in Twins (NUGAT) study, GG genotype of rs4343 of ACE was associated with increased risk for hypertension and CVD in individuals on high-saturated-fat diet [48••] . The proposed mechanisms seem to involve high fat in activating RAS in adipocytes through toll-like 4 receptors and NFkB signaling [49] . The association of salt with hypertension is well known and there have been some efforts to elucidate the genetic contribution to salt-sensitive blood pressure (SSBP) changes. In a recent study, variants in estrogen receptor (ESR2) were implicated in SSBP. Estrogen-replete women with ESR2 rs10144225 minor allele were more salt-sensitive than men or postmenopausal women [50] . The Genetic Epidemiology Network of Salt Sensitivity (GenSalt) study was designed to understand the basis of salt-sensitivity in~2000 individuals administered a 7-day low-sodium diet followed by a 7-day high-sodium diet. This study found SSBP to be associated with rare variants in three genes of a group of renal epithelial sodium channels (ENaC) [51] . Using a blood pressure GRS, the same group found that a blood pressure GRS to be inversely related to SSBP [52] .
Dyslipidemia
Elevated circulating triglycerides and LDL cholesterol levels and lower HDL cholesterol increase the risk for CVD. Studies have shown that polymorphisms in genes associated with fatty acid metabolism interact with dietary fat intake to affect circulating lipid concentrations [53] [54] [55] [56] . In a study where 208 participants were given fish oil supplementation for 6 weeks, plasma triglyceride levels decreased in individuals with retinoid × receptor alpha (RXRA) SNPs. They found that individuals with CT or TT genotypes of RXRA SNP rs11185660 had decreased plasma triglycerides as compared to those with CC genotypes following fish oil intake [53] . They also found significant increase in the expression of carnitine palmitoyl transferase 1 A (CPT1A) gene following the intake of fish oil. Similarly, people with the E4 allele of apolipoprotein E (APOE) were less responsive in their plasma PUFA concentrations to dietary fat manipulation and more so if they were overweight [54, 55] . PUFAs such as ω3 and ω6 fatty acids are essential fatty acids that need to be provided through diet. They are part of membrane structure and have roles in lipid metabolism, blood clotting, blood pressure, and inflammation [56] . They have also been shown to interact with fatty acid desaturase (FADS) variants to affect low-density lipoprotein (LDL) cholesterol concentrations and obesity phenotype [85, 86] . Additionally, carbohydrate intake has also been reported to interact with glucokinase genetic variation to affect plasma triglycerides [57] .
Inflammation, Oxidative Stress, and Other CVD Risk Factors
Diet × gene interactions are believed to affect inflammation and oxidative stress, which contribute significantly to the development and progression of CVD [58] [59] [60] [61] . However, nutrigenetics/nutrigenomics studies in humans are very limited. In elderly women, vitamin D 3 supplementation reduced inflammatory markers and increased total antioxidant capacity in those with vitamin D insufficiency. Those with the BB/Bb genotype of vitamin D receptor (VDR) gene were more responsive to the supplementation compared to those with bb genotype [58] . In a Japanese study, genetic variation in oxidative risk-related genes carnosine dipeptidase (CNDP1) and carnosine cellular non-specific dipeptidase (CNDP2) were correlated with obesity risk but only in individuals with high carbohydrate intake and low carotene intake [59] . Although it is believed that diet can modify the relationship between oxidative stress and gene polymorphisms, very few studies have been conducted in this regard. There have been some studies related to the supplementation of zinc, copper, and selenium and their interaction with gene polymorphisms on oxidative stress, particularly interleukin 6 (IL6) and metallothionein 1A (MT1A) genes [60, 61] . Elderly people carrying GG genotypes may need zinc supplementation to improve their stress response because GC/CC genotypes display better stress response than GG carriers [60] . Similarly, MT1A +647A/C is associated with zinc deficiency. Thus, IL6 and MT1A polymorphisms can be used to identify old people for dietary intervention [61] .
There has been much interest in studying the effects of dietary patterns in addition to individual nutrients. Several dietary patterns have been shown to be beneficial for cardiovascular health. Some of these, such as Mediterranean, Prudent, and Dietary Approaches to Stop Hypertension (DASH) diets, have been extensively researched. All of them emphasize the beneficial effects of whole grains and fruits and vegetables and deleterious effects of sodium, saturated fats, and sugars. One of the prominent trials highlighting the beneficial effects of the Mediterranean diet is PREDIMED (Prevencion con Dieta Mediterranea) trial [62, 63] . The PREDIMED trial was conducted to determine the effect the type of fat on CVD mortality. Spanish individuals at high risk for CVD were asked to partake Mediterranean diet supplemented with olive oil or nuts or low fat [62] . The intervention was based on provision of olive oil or nuts and education. The primary endpoint was the rate of major CV events [63] . Ortega-Azorin and colleagues have found that the association between FTO-rs9939609 and MC4R-rs17782313 and T2D was stronger when the adherence to a Mediterranean diet was low [64] . In fact, several studies from the PREDIMED trial have demonstrated the effectiveness of a Mediterranean meal in modulating genetic association of obesity, diabetes, and other CVD risk factors [65] [66] [67] . Individuals on Mediterranean diet and G-carriers of rs382316 of Max-like protein X interacting protein-like (MLXIPL) reduced their triglycerides and their risk for myocardial infarction as compared to CC carriers [68•] . The DASH was a multi-center study to test the effects of healthy dietary patterns on hypertension [69] . A comparison between individuals on Western diet and DASH diet showed that the effect of sodium intake on blood pressure differed based in their genotypes mainly in angiotensinogen, beta2-adrenergic receptor, and kallikrein loci [70] . In addition, interaction between low fat and hypocaloric diets have been shown to interactwith circadian locomotor cycles kaput (CLOCK) and BDNF SNPs to affect obesity, inflammation and diabetes phenotypes (Table 1) [81, 82, 87, 88] 
Nutrigenomics of CVD Risk Factors
Nutrigenomics is another aspect of nutritional genomics and refers to the study of effects of nutrients on the expression of individual genes [7] . Nutrigenomics studies in humans typically use either whole blood or peripheral blood mononuclear cells (PBMCs) and focus on changes in PBMC gene expression after intervention with nutrients or meals [71] [72] [73] . Vedin et al. [71] found inflammation-related genes to be downregulated in Alzheimer's patients with ω3 PUFA supplementation. Likewise, Rudkowska et al. [72] found a positive change in CVD markers. The circulating levels of high-density lipoprotein (HDL) cholesterol increased with a parallel reduction in triglycerides and expression of genes related to oxidative stress and inflammation. Furthermore, positive changes were also observed in inflammation-related miRNA and cytokine gene expression with a 1-year supplementation with grape extract [73] . A study comparing the effects of Mediterranean with Western meal on inflammation and oxidative stress found that the Mediterranean diet significantly reduced ox-LDL and expression of inflammation and oxidative stress-related genes [74] .
In 30 individuals participating in a study from the Quebec City Metropolitan area, distinct gene expression patterns were found between individuals on Western versus Prudent diet. The Western diet was characterized by high intake of refined grains, desserts, sweets, and processed meats, while the Prudent diet featured high intake of vegetables, fruits, and whole grain products [75] . Most of the genes that showed significant differences were related to inflammation and immune response, cancer, and CVD. In another study in which individuals were on Mediterranean diet as part of the PREDIMED trial, the observed alterations in PBMC gene expressions were in cardiovascular pathways [76] . Ellsworth et al. [77••] tested the short-term and long-term effects of lifestyle modifications in which 63 individuals underwent lifestyle modification (low-fat vegetarian diet, increased physical activity, 1 h of stress management, and weekly group support sessions) versus 63 matched controls. There were no changes in CVD-related circulating biomarkers or ACE angiotensin-converting enzyme; BDNF brain-derived neurotrophic factor; CLOCK circadian locomotor output cycles kaput; FADS1 fatty acid desaturase 1; FTO fat mass and obesity associated; BMI body mass index; LDLc low density lipoprotein cholesterol gene expression in controls. In contrast, the group with lifestyle modification experienced reduction in expression of proinflammatory genes.
Conclusions
The view that diet influences health is an ancient notion but our understanding of the various mechanisms is still evolving. Nutrigenetics and nutrigenomics are two areas which are leading the way in addressing the questions of which components of diet most influence health, what are the underlying mechanisms, and which individuals are more/less susceptible to nutrient-associated disease [78, 79•] . The role of nutritional genomics is well established in monogenic diseases such as phenylketonuria, lactase deficiency, and glucose-6-phosphate deficiency, however, the field is still developing with respect to complex diseases such as CVD.
Although there is ample scientific evidence indicating that the genetic susceptibility to CVD can be modified by diet (summarized in Table 1 ), we are still not at a stage where this information is easily translated into dietary plans. Most of the previous results are based on cohort studies that rely on selfreported data derived from 24-hr diet recalls and food frequency questionnaires. Thus, there is a need for better approaches to achieve precision in dietary data collection and update computational approaches. The selection of SNPs for gene × nutrient interaction analyses also needs to be streamlined.
Currently, variants to be tested are selected based on the statistical significance in genetic studies and not necessarily, on biologically meaningful SNPs in the process. Additionally, follow-up studies may not be sufficiently powered for replications, variation in dietary exposure may be too great and some of the results may be replicable only in a subgroup because of their particular genetic patterns.
There is a need for more intervention studies, specifically randomized and controlled clinical trials, generating valid and precise information that can be utilized by dietitians in their practice. Some nutritional interventions can be very effective, with the likely effect size of some genotype-specific nutritional interventions being as large as that of medical treatments. Secondly, misconceptions about this field (nutrigenetics and nutrigenomics) and misinterpretation of outcomes are major barriers to the translation or implementation of these results with respect to public health. Therefore, we need to create awareness and emphasize health education, taking into consideration the social and ethical implications. Overall, this is an exciting time for nutritional genomics. Consistency of significant results by replication studies in separate cohorts and emphasis on biologically relevant and statistically significant variants will eventually lead to CVD prevention measures and generate hypotheses for clinical trials for genotype-guided CVD management.
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